Wedbush Reiterates Outperform on Sutro Biopharma, Maintains $60 Price Target
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $60 price target.
Read original at benzingaStocks · News reference
Citizens Maintains Market Outperform on Sutro Biopharma, Lowers Price Target to $34
Citizens analyst Reni J. Benjamin maintains Sutro Biopharma (NASDAQ:STRO) with a Market Outperform and lowers the price target from $41 to $34.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 2:01 PM
- Checked
- Aug 13, 2026, 2:01 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why is Sutro Biopharma Stock Falling On Wednesday?
Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.
Read original at benzingaGold Gains 1%; Performance Food Group Shares Fall After Q4 Results
Dow Jones up 0.1%, NASDAQ up 0.47%, S&P 500 up 0.24%. Tech stocks up 1.1%, communication services down 1.3%. Performance Food Group shares down 6% after reporting earnings miss. AII up 17%, EROC up 20%, BOXL up 69%. NCMI down 31%, UAMY down 22%, STRO down 16%. Oil down 0.1%, gold up 1.1%. Eurozone mixed, Asian markets close mixed. CPI rises 3.4% year-over-year in July.
Read original at benzinga